Advanced search
1 file | 985.49 KB

Blocking HCV entry as potential antiviral therapy

Koen Vercauteren (UGent) , Geert Leroux-Roels (UGent) and Philip Meuleman (UGent)
(2012) FUTURE VIROLOGY. 7(6). p.547-561
Author
Organization
Abstract
Infections with HCV represent a major global health problem. End-stage liver disease caused by chronic HCV infection is the most common indication for liver transplantation. Limited efficacy and severity of side effects hamper the use of pegylated interferon combined with ribavirin in a liver transplant setting. Therefore, new therapeutic options should be made available. Viral entry, the first step of the viral life cycle, represents an interesting target for therapeutic intervention. Understanding the mechanisms of viral entry is necessary to define the viral and cellular factors involved. In this review, we summarize these factors, highlight their potential as therapeutic targets and review the current (pre)clinical development of molecules that interfere with HCV entry.
Keywords
viral entry, liver transplantation, viral hepatitis, HEPATITIS-C-VIRUS, HUMAN MONOCLONAL-ANTIBODIES, B TYPE-I, HIGH-DENSITY-LIPOPROTEIN, SCAVENGER RECEPTOR-BI, PRIMARY HUMAN HEPATOCYTES, E2 ENVELOPE GLYCOPROTEIN, SERUM AMYLOID-A, NEUTRALIZING ANTIBODIES, CELL ENTRY, humanized mice, antiviral therapy

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 985.49 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Vercauteren, Koen, Geert Leroux-Roels, and Philip Meuleman. 2012. “Blocking HCV Entry as Potential Antiviral Therapy.” Future Virology 7 (6): 547–561.
APA
Vercauteren, K., Leroux-Roels, G., & Meuleman, P. (2012). Blocking HCV entry as potential antiviral therapy. FUTURE VIROLOGY, 7(6), 547–561.
Vancouver
1.
Vercauteren K, Leroux-Roels G, Meuleman P. Blocking HCV entry as potential antiviral therapy. FUTURE VIROLOGY. 2012;7(6):547–61.
MLA
Vercauteren, Koen, Geert Leroux-Roels, and Philip Meuleman. “Blocking HCV Entry as Potential Antiviral Therapy.” FUTURE VIROLOGY 7.6 (2012): 547–561. Print.
@article{3131784,
  abstract     = {Infections with HCV represent a major global health problem. End-stage liver disease caused by chronic HCV infection is the most common indication for liver transplantation. Limited efficacy and severity of side effects hamper the use of pegylated interferon combined with ribavirin in a liver transplant setting. Therefore, new therapeutic options should be made available. Viral entry, the first step of the viral life cycle, represents an interesting target for therapeutic intervention. Understanding the mechanisms of viral entry is necessary to define the viral and cellular factors involved. In this review, we summarize these factors, highlight their potential as therapeutic targets and review the current (pre)clinical development of molecules that interfere with HCV entry.},
  author       = {Vercauteren, Koen and Leroux-Roels, Geert and Meuleman, Philip},
  issn         = {1746-0794},
  journal      = {FUTURE VIROLOGY},
  keyword      = {viral entry,liver transplantation,viral hepatitis,HEPATITIS-C-VIRUS,HUMAN MONOCLONAL-ANTIBODIES,B TYPE-I,HIGH-DENSITY-LIPOPROTEIN,SCAVENGER RECEPTOR-BI,PRIMARY HUMAN HEPATOCYTES,E2 ENVELOPE GLYCOPROTEIN,SERUM AMYLOID-A,NEUTRALIZING ANTIBODIES,CELL ENTRY,humanized mice,antiviral therapy},
  language     = {eng},
  number       = {6},
  pages        = {547--561},
  title        = {Blocking HCV entry as potential antiviral therapy},
  url          = {http://dx.doi.org/10.2217/FVL.12.47},
  volume       = {7},
  year         = {2012},
}

Altmetric
View in Altmetric
Web of Science
Times cited: